688185 康希诺
已收盘 01-14 15:00:01
资讯
新帖
简况
康希诺：公司不持有磐如生物科技（天津）有限公司的股份
证券日报 · 01-13 22:06
康希诺：公司不持有磐如生物科技（天津）有限公司的股份
康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域
证券日报 · 01-13 21:09
康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域
康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中
证券日报 · 01-13 19:36
康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中
每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准
证券之星 · 01-11
每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准
康希诺：2025年公司4款候选产品已获得批准IND/NDA
证券日报 · 01-06
康希诺：2025年公司4款候选产品已获得批准IND/NDA
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
证券日报 · 01-06
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
证券日报 · 01-06
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
证券日报 · 01-06
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
证券日报 · 01-06
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
美股速递 · 01-05
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
证券日报 · 2025-12-23
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%
证券之星 · 2025-12-19
康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%
康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组
智通财经 · 2025-12-19
康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组
智通港股通资金流向统计(T+2)|12月8日
智通财经 · 2025-12-08
智通港股通资金流向统计(T+2)|12月8日
康希诺跌2.50% 2020年上市募52亿中信证券保荐
中金财经 · 2025-12-03
康希诺跌2.50% 2020年上市募52亿中信证券保荐
康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%
证券之星 · 2025-11-27
康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%
康希诺：关于回购A股股份注销实施的公告
证券日报 · 2025-11-26
康希诺：关于回购A股股份注销实施的公告
每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床
证券之星 · 2025-11-16
每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床
康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组
智通财经 · 2025-11-13
康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组
康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%
证券之星 · 2025-11-11
康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%
加载更多
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":71.99,"timestamp":1768374001000,"preClose":69.11,"halted":0,"volume":4925179,"delay":0,"changeRate":0.0417,"floatShares":113999999,"shares":247000000,"eps":-0.575,"marketStatus":"已收盘","change":2.88,"latestTime":"01-14 15:00:01","open":69.55,"high":74.44,"low":69.4,"amount":355000000,"amplitude":0.0729,"askPrice":71.99,"askSize":3,"bidPrice":71.9,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-0.575,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":69.11,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":76.02,"lowLimit":62.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":3.61,"roa":"--","roe":"0.29%","epsLYR":-1.53,"committee":0.481663,"marketValue":17785000000,"turnoverRate":0.0431,"status":0,"afterMarket":{"amount":0,"volume":0,"close":71.99,"buyVolume":0,"sellVolume":0,"time":1768376037558,"indexStatus":"已收盘 01-14 15:30:00","preClose":69.11},"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":38.78,"timestamp":1768378086007,"preClose":37.54,"halted":0,"volume":1505406,"delay":0,"premium":"-51.84"},"floatMarketCap":8234000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2603680381","title":"康希诺：公司不持有磐如生物科技（天津）有限公司的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680381","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680381?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:06","pubTimestamp":1768313165,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司不持有磐如生物科技（天津）有限公司的股份，与其为合作关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617716055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159837","688185"],"gpt_icon":0},{"id":"2603948684","title":"康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2603948684","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603948684?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:09","pubTimestamp":1768309778,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司将在专注做好主营业务的基础上，利用搭建的mRNA技术平台拓展更多应用领域，关注潜在的商业机会，以发挥该技术平台的价值。如有阶段性进展，将及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617669884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2603686875","title":"康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686875","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603686875?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:36","pubTimestamp":1768304198,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司的吸附破伤风疫苗的药品注册申请正在正常审核中，会根据药审要求及时提供相关资料，以保障审核顺利进行。如有阶段性进展，将及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617599321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159646","688185"],"gpt_icon":0},{"id":"2602536997","title":"每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536997","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536997?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:54","pubTimestamp":1768074850,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，康希诺报收于68.69元，较上周的62.85元上涨9.29%。本周关注点公司公告汇总：24价肺炎球菌多糖结合疫苗获临床试验批准。公司公告汇总：该24价肺炎疫苗采用双载体技术，适用于2月龄及以上人群。康希诺H股公告截至2025年12月31日，康希诺生物股份公司H股总数为132,670,900股，A股总数为114,372,901股，法定注册资本为人民币247,043,801元，各项股份均无变动。2025年A股限制性股票激励计划首次授予2,054,600股，但本月未因此发行新股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688185"],"gpt_icon":0},{"id":"2601890033","title":"康希诺：2025年公司4款候选产品已获得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601890033?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端，2025年公司4款候选产品已获得批准IND/NDA，以及启动2个新的临床试验，以2026年设置的业绩考核目标A档来看，2026年至少包括5款候选产品获得批准IND、获得批准NDA，以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进，公司也会和药监、中检院及临床试验合作方等积极沟通，以期顺利推进相应候选产品的研发里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688185","IND"],"gpt_icon":0},{"id":"2601897404","title":"康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897404","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897404?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:08","pubTimestamp":1767704903,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准，并于同年12月启动I期临床试验，以评估其在2月龄~6岁人群中接种的安全性及免疫原性，与现有已上市及在研联苗产品形成差异化竞争。该联苗从临床需求的角度出发，考量了婴幼儿所需接种的疫苗品类，预期未来可提升婴幼儿群体接种的便利性和依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2601897400","title":"康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897400","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897400?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:07","pubTimestamp":1767704853,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司产品曼海欣?为目前国内唯一获批上市的四价流脑结合疫苗，是定位于中高端婴幼儿疫苗市场的产品，经过近几年的品牌建设、学术推广及市场教育，曼海欣?在国内的市场接受度以及渗透率逐步提升，其销售收入的稳步增长也证实了国内市场对于优质、高端的婴幼儿疫苗的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","688185","BK0239"],"gpt_icon":0},{"id":"2601892483","title":"康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892483","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892483?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:40","pubTimestamp":1767703205,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，公司将在专注做好主营业务的基础上，利用搭建的mRNA技术平台在治疗领域持续探索更多适应症，如有阶段性进展，将会及时公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610427379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2601643891","title":"康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2601643891","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601643891?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:40","pubTimestamp":1767699626,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，中检院自2021年4月中旬起不再公布疫苗产品的批签发数量，公司会参考同行的信息公示处理方式执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610380937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","688185","BK0239"],"gpt_icon":0},{"id":"1147976460","title":"康希诺生物获中国国家药监局批准开展PCV24相关临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1147976460","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147976460?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:56","pubTimestamp":1767603417,"startTime":"0","endTime":"0","summary":"康希诺生物宣布，公司已正式获得中国国家药品监督管理局（NMPA）的临床试验批准，将启动针对PCV24（24价肺炎球菌结合疫苗）的相关临床研究。\n此次获批标志着康希诺在肺炎疫苗领域的研发取得重要进展，为后续产品上市奠定基础。PCV24疫苗若研发成功，有望为更广泛人群提供肺炎球菌感染的预防保护。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2593968413","title":"康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2593968413","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593968413?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:42","pubTimestamp":1766497324,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，康希诺在互动平台回答投资者提问时表示，公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作，持续与意向国家接触及探讨合作模式，并协同合作方开展临床试验及注册准入等相关工作，以加快公司产品的海外布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599763762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239","159646"],"gpt_icon":0},{"id":"2592985971","title":"康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592985971","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592985971?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:24","pubTimestamp":1766154282,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，康希诺报收于63.4元，较前一交易日下跌0.24%，最新总市值为156.63亿元。该股当日开盘63.36元，最高64.46元，最低63.36元，成交额达6440.61万元，换手率为0.88%。近日，康希诺生物股份公司发布公告称，其吸附无细胞百（组分）白破b型流感嗜血杆菌（结合）-ACYW135群脑膜炎球菌（结合）联合疫苗已启动I期临床试验，并完成首例受试者入组。公告提示，疫苗研发存在周期长、风险高等不确定性，敬请投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2592154407","title":"康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2592154407","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592154407?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:36","pubTimestamp":1766133419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司的吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗(简称“DTcP-Hib-MCV4联合疫苗”)于近日正式启动I期临床试验，并完成首例受试者入组。I期临床试验为评价DTcP-Hib-MCV4联合疫苗在2月龄~6岁人群中接种的安全性及免疫原性的随机、部分盲法、剂量探索、阳性/安慰剂对照的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2589801348","title":"智通港股通资金流向统计(T+2)|12月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801348","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801348?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:31","pubTimestamp":1765150261,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月3日,小米集团-W、阿里巴巴-W、美团-W南向资金净流入金额位列市场前三，分别净流入8.71 亿、4.25 亿、2.99 亿腾讯控股、中芯国际、紫金矿业南向资金净流出金额位列市场前三，分别净流出-7.34 亿、-4.22 亿、-1.91 亿在净流入比方面，标智香港100、南方港美科技、新华文轩以100.00%、74.54%、72.97%位列市场前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999007991.SGD","LU1794554557.SGD","LU0329678170.USD","LU0192582467.USD","LU2237443978.SGD","LU0048580855.USD","LU0572944931.SGD","LU0140636845.USD","BK1109","LU0254981946.USD","LU2213484517.USD","LU0862451837.USD","BK1561","SG9999001903.USD","LU0823413587.USD","LU0345769128.USD","LU1880383440.USD","LU1224709979.USD","LU2357305700.SGD","LU0469268626.HKD","LU0823038988.USD","LU0164872284.USD","LU0348723411.USD","LU0797268264.HKD","BK1224","LU2087589342.USD","LU0345776255.USD","LU2039709279.SGD","LU1064130708.USD","LU1813983027.USD","LU1242518931.SGD","LU0880133367.SGD","LU1951186391.HKD","LU0107464264.USD","IE00BQXX3C00.GBP","LU0882747503.HKD","LU0261950983.USD","HK0000320223.HKD","LU0463099449.HKD","LU0499858602.USD","BK1104","BK1617","LU2247934214.USD","BK1512","LU0417516738.SGD","LU0054450605.USD","BK1233","SGXZ99366536.SGD","HK0000252152.HKD","LU0047713382.USD","LU0127658192.USD","LU0594300179.USD","SG9999014906.USD","IE00B0169L03.USD","LU0823039010.USD","BK1505","IE0031814852.USD","LU0039217434.USD","LU0348783662.USD","BK1592","BK1142","LU0117844026.USD","LU0266512473.USD","SG9999004311.SGD","LU0823041008.USD","LU0348735423.USD","LU0106252389.USD","IE0003795394.USD","LU1115378108.SGD","LU2125910500.SGD","LU0188438112.USD","LU2237443895.HKD","03442","LU1629966141.USD","LU2097828557.USD","601899","LU2237443382.USD","SG9999000327.SGD","HK0000320264.USD","LU0132412106.USD","BK1528","LU0261947096.USD","LU0456846285.SGD","LU0593848301.USD","LU0011963245.USD","BK1570","LU0320764755.SGD","LU0516423174.USD","SG9999015952.SGD","LU0130518102.USD","SG9999012744.USD","LU0823397285.USD","LU0516422440.USD","LU0878005551.USD","LU1868838027.USD","LU0143863784.USD","LU0683595622.HKD","LU3063872942.SGD","LU0211331839.USD","LU0049853897.USD","LU2462611646.USD","LU0287142896.SGD","LU1282649067.USD","LU2177674079.SGD","SG9999003461.SGD","SG9999002463.SGD","BK1119","LU0501845795.SGD","LU0359201612.USD","IE0032834883.USD","ZIJMY","LU2476274720.SGD","LU1224444064.USD","LU0784639295.USD","LU0572939691.SGD","BK1591","LU0196878994.USD","BK1555","BK1608","BK1521","IE00BF5LJ272.USD","LU0456827905.SGD","LU1785774172.SGD","LU1439103000.SGD","LU0054237671.USD","SG9999002950.SGD","LU0588545490.SGD","LU1282651048.USD","LU1733274473.HKD","LU0051755006.USD","LU0607220059.USD","BK1116","BK1583","LU0516423091.SGD","LU0516422366.SGD","LU1366334578.USD","BK1236","LU1048596156.SGD","BK1516","LU0197773673.USD","LU0633140727.USD","SG9999004220.SGD","HK0000252160.HKD","LU0307460666.USD","XIACY","80883","IE00BMPRXR70.SGD","LU0164865239.USD","BK1240","LU1880398554.USD","LU0314109678.HKD","LU0210527791.USD","LU0417516902.SGD","LU0106259558.USD","LU0348805143.USD","LU1211504680.USD","SG9999002828.SGD","LU1323998911.USD","LU1226288097.SGD","IE00B031HY20.USD","LU0540923850.HKD","LU1102505762.USD","LU2106854487.HKD","LU0791591158.USD","LU1196710864.SGD","LU1634259557.SGD","LU2097829019.USD","SG9999014674.SGD","BK1214","02825","LU1226287875.USD","HK0000165453.HKD","BK1557","SG9999001226.SGD","IE0034224299.USD","SG9999017495.SGD","LU1993786604.SGD","BK1515","LU0456854461.SGD","LU0577902611.USD","LU0862451753.SGD","BK1133","BK1500","LU0821914370.USD","LU0328353924.USD","SGXZ62798434.SGD","BK1207","BK1523","BK1590","LU2317271919.USD","BK1238","LU0918141887.USD","LU2449936058.SGD","LU0348766576.USD","LU0737861699.HKD","IE00BQXX3D17.EUR","BK1560","LU0531970944.HKD","LU0143863198.USD","LU1974910355.USD","LU2097828805.USD","LU0164880469.USD","SG9999012710.SGD","SGXZ90724238.SGD","BK1225","LU0509642566.USD","LU0293314216.USD","LU2293587155.HKD","SG9999001846.SGD","LU0175139822.USD","LU0348788117.USD","LU1226287792.SGD","LU1655091459.SGD","LU0608807433.USD","LU0348767384.USD","LU0327786744.USD","BK1589","LU0315178854.USD","LU1152091754.HKD","LU1196710195.USD","600012","BK1586","SG9999000459.SGD","LU1868837722.USD","LU0823426480.USD","BK1514","LU1316542783.SGD","LU0791590937.USD","LU2362541273.HKD","SG9999015945.SGD","BK1609","BK1249","IE00B8L5B284.USD","HK0000306685.HKD","00995","BK1181","LU1917777945.USD","LU0244354667.USD","IE00B031J352.USD","LU1769817096.USD","IE0008369823.USD","LU1718418525.SGD","LU0259732245.USD","BK1506","LU0251144936.SGD","LU1733274390.USD","LU0264606111.USD","LU1282648689.USD","LU2125910849.SGD","81810","LU2133065610.SGD","LU0348827113.USD","LU0642271901.SGD","BK1526","LU0210526637.USD","LU0577902298.EUR","LU0831093199.SGD","LU2399975544.HKD","LU1008478684.HKD","KSTmain","LU0203345920.USD","LU2265009873.SGD","BK1607","BK1095","IE00BPRC5H50.USD","LU0502904849.HKD","LU1188198961.HKD","LU1831875114.USD","SG9999001093.SGD","SG9999001069.SGD","BK1610","LU0608807946.USD","BK1502","LU1226288170.HKD","LU0738912210.USD","LU0823397103.USD","SG9999001689.USD","LU2257852520.SGD","SG9999000418.SGD","LU2279701549.SGD","LU0029875118.USD","LU0359202008.SGD","LU0541501648.USD","LU1515016050.SGD","IE0003851619.USD","LU0640798160.USD","GB00BDT5M118.USD","LU0541502299.USD","LU0345769631.USD","LU0348783233.USD","IE00B97KM107.HKD","BK1221","LU0633140560.USD","BK1185","LU1196710351.USD","LU1720051108.HKD","LU2008162690.USD","LU1956131251.USD","LU0326948709.USD","LU1102505929.USD","LU0235996351.USD","LU0163747925.USD","LU0708995583.HKD","LU0873338254.USD","SG9999006514.SGD","LU0856984785.SGD","LU1497733557.USD","LU1568876335.HKD","LU0588545730.USD","LU1226287529.USD","IE0008368742.USD","LU1282651121.HKD","LU2488822045.USD","LU2543165471.USD","IE00B0JY6N72.USD","LU1568876251.USD","BK1618","BK1566","IE00BZ08YR35.GBP","BK1513","SG9999015978.USD","LU0414403682.SGD","LU1282649810.SGD","LU1725190679.HKD","IE0032431581.USD","LU0345780281.USD","LU1044874839.SGD","LU1251922891.USD","LU0431992006.USD","LU0128522157.USD","LU0228367735.SGD","BK1584","BK1588","LU0650527681.SGD","LU1734074674.USD","LU2778985437.USD","IE00BMPRXN33.USD","LU0072462343.USD","LU1303224171.USD","LU0348814723.USD","LU0345775950.USD","LU0577902371.SGD","LU0348825331.USD","SG9999018865.SGD","BK1574","LU1282649141.HKD","IE00BVYPNP33.GBP","LU0070217475.USD","LU2051468812.USD","LU0918141705.HKD","LU1152091168.USD","BK1567","LU1048484197.HKD","LU0169518387.USD","LU1504937902.USD","81024","LU0572940350.SGD","BK1231","LU0828237510.HKD","LU1235295612.USD","LU1883866441.USD","LU0315179316.USD","LU2362541513.USD","LU0823040885.USD","LU0348784397.USD","LU0229945570.USD","LU1242518857.USD","LU0594300419.USD","LU1770036033.HKD","LU0326950275.SGD","LU0651947912.USD","LU1046422090.SGD","LU1481107354.HKD","LU2045819591.USD","BK1161","BK1130","BK1163","LU0972618739.USD","LU1051769294.HKD","LU0890818403.SGD","BK1614","LU0269904917.USD","LU0648000940.SGD","SG9999014914.USD","BK1536","LU1105468828.SGD","LU0345780521.USD","00811","688185","LU0819123356.HKD","LU0117841782.USD","SG9999006597.SGD","LU1051768304.USD","LU1048588211.SGD","LU0449515922.USD","LU0096374516.USD","LU0441854154.USD","89988","LU0211977185.USD","LU0543330483.HKD","LU0543330566.HKD","LU0203347892.USD","LU2362540622.SGD","LU0898667661.SGD","LU0588546209.SGD","LU0072913022.USD","HK0000306701.USD","IE0001KFT4U8.USD","BK1235","LU0886674414.USD","LU0396098781.USD","LU0651946864.USD","SG9999012728.SGD","LU0049112450.USD","LU0762542818.HKD","LU0080751232.USD","LU1634259391.SGD","LU0865486749.SGD","LU1810669033.SGD","LU0823426308.USD","LU1366334651.USD","LU0173614495.USD","BK1196","IE00BQXX3F31.USD","LU0084288322.USD","LU1770034418.SGD","LU1880398471.USD","IE0008368411.USD","03143","LU0531971595.HKD","IE00B3M56506.USD","LU2097828474.EUR","LU1675838814.USD","LU0320764243.SGD","SG9999001051.SGD","LU2251237306.USD","LU0819121731.USD","BK1587","LU0149721374.USD","LU1960683339.HKD","LU0329678337.USD","IE00BZ08YS42.EUR","02899","LU0384037296.USD","LU0181495838.USD","IE00B0169N27.USD","LU2148510915.USD","SG9999015986.USD","LU0672654166.SGD","BK1141","LU2237443549.SGD","LU2023250504.SGD","LU0128522744.USD","LU0499858438.USD","LU0214875030.USD","LU0577902454.USD","LU0228659784.USD","BK1152","BK1184","LU0165289439.USD","HMTD.SI","BK1544","LU2097828714.EUR","HK0000500386.USD","IE00B5MMRT66.SGD","IE00BGHQDM52.EUR","LU0708995153.HKD","BK1193","LU0675040207.SGD","LU0289960550.SGD","LU0266512127.USD","LU0210533765.USD","LU1719994722.HKD","LU1688375341.USD","LU0762540952.USD","LU1961090484.USD","688981","BK1575","IE00B067MR52.USD","LU1328277881.USD","LU2237443465.HKD","LU0828238088.HKD","BK1227","LU0868486357.SGD","LU1522347837.USD","LU1880383366.USD","SG9999018857.SGD","LU0823413660.USD","LU2498475776.HKD","SG9999013353.USD","LU2226246903.HKD","LU0359201885.HKD","LU0871576103.HKD","LU0589944569.HKD","LU1808992512.USD","LU0979878070.USD","HBBD.SI","SGXZ81514606.USD","LU0149534421.HKD","LU1044875133.USD","LU0762541174.USD","LU0231483743.USD","LU0456842615.SGD","LU1642822792.SGD","LU1720050803.USD","LU0477156797.USD","BK1198","LU0029874905.USD","LU0630378692.HKD","LU0737861772.HKD","LU2242644610.SGD","IE0003895053.USD","LU1023057109.AUD","BK1517","LU0630378429.USD","LU0561508036.HKD","LU0634319403.HKD","LU2237443622.USD","LU1226288253.USD","BK1604","LU1201861165.SGD","IE00BWDBJ730.SGD","00754","LU1804176565.USD","BK1550","SG9999014880.SGD","SGXZ86797644.SGD","LU0516422952.EUR","LU1497734951.SGD","06185","IE00B543WZ88.USD","BK1134","SGXZ51526630.SGD","LU0786609619.USD","SG9999014898.SGD","LU1814569148.SGD","BK1531","HTCD.SI","LU0878004406.USD","BK1191","LU1044876610.USD","LU0048597586.USD","BK1568","LU0648948544.HKD","LU0611395673.USD","IE00B031HW06.USD","IE00B19Z5X02.USD","LU0831103253.SGD","LU1807302812.USD","LU0130103400.USD","LU1439102457.SGD","LU1981816686.USD","IE0008368304.USD","IE00BGV7N243.SGD","LU0106959298.USD","LU2152927971.USD","LU0052750758.USD","601811","LU1548497426.USD","IE00B29SXG58.USD","SG9999002562.SGD","LU1769817179.HKD","IE00BMCWC346.EUR","LU0061477393.USD","LU0488056044.USD","LU0985320562.USD","LU0067412154.USD","LU2097828631.EUR","LU0320764599.SGD","LU0348816934.USD","IE00BYV24P56.USD","LU0417516571.SGD","LU2251237488.HKD","IE00BVYPNQ40.USD","LU0577902538.SGD","LU1720051017.SGD","LU1328615791.USD","LU1064131003.USD","LU0828237940.HKD","LU0700851271.USD","LU0048388663.USD","LU2476274308.USD","BK1175","LU1868837565.USD","IE00B8HQ1Z84.USD","SGXZ31699556.SGD","BK1501","LU0043850808.USD","01810","LU0455707207.USD","HXXD.SI","BK1615","LU0588545904.SGD","IE00BZ08YT58.USD","LU0197773160.USD","BK1594","IE0009570106.USD","SG9999012736.USD","IE00BQJZWZ67.USD","LU0449509016.USD","LU0370786039.SGD","LU0605514214.HKD","LU1497733631.SGD"],"gpt_icon":1},{"id":"2588014445","title":"康希诺跌2.50% 2020年上市募52亿中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014445","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014445?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:22","pubTimestamp":1764753726,"startTime":"0","endTime":"0","summary":"中国经济网北京12月3日讯 康希诺 今日股价下跌，截至收盘报65.63元，跌幅2.50%。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251203/31841808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06030","LU1720050803.USD","LU2289578879.USD","BK0012","BK0196","BK0239","BK0188","LU1997245094.SGD","BK1564","BK0028","LU1655091616.SGD","BK1516","BK1521","LU1328615791.USD","688185","LU1997244956.HKD","LU1997245177.USD","BK0183","LU2148510915.USD","600030","LU1255011170.USD","LU1064130708.USD","BK0276","LU0405327494.USD","LU1794554557.SGD","LU2495084118.USD","LU0405327148.USD","LU1064131003.USD","BK1147"],"gpt_icon":1},{"id":"2586225544","title":"康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586225544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586225544?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:16","pubTimestamp":1764252987,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，康希诺报收于68.6元，较前一交易日下跌0.22%，最新总市值为169.47亿元。该股当日开盘68.6元，最高69.36元，最低68.16元，成交额达7180.52万元，换手率为0.91%。近日，康希诺生物股份公司召开2025年第二次临时股东大会，审议通过了关于取消监事会、修订《公司章程》及其附件并办理工商变更登记的议案，修订部分公司治理制度的议案，以及使用公积金弥补亏损的议案。公告显示，本次会议表决程序合法有效，所有议案均获通过，无被否决议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2586250392","title":"康希诺：关于回购A股股份注销实施的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250392","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586250392?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:39","pubTimestamp":1764164394,"startTime":"0","endTime":"0","summary":"证券日报网讯11月26日晚间，康希诺发布公告称，本次回购股份注销日期为2025年11月27日，股份注销数量为406，098股A股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575664492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","159982","399300","BK0239"],"gpt_icon":0},{"id":"2583659452","title":"每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659452","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659452?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:36","pubTimestamp":1763231775,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，康希诺报收于75.08元，较上周的74.27元上涨1.09%。本周，康希诺11月14日盘中最高价报77.1元。本周关注点公司公告汇总：康希诺吸入用肺结核疫苗在印度尼西亚启动I期临床试验并完成首例受试者入组。公司公告汇总：康希诺召开2025年第二次临时股东大会，审议取消监事会及修订《公司章程》等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688185","BK0239"],"gpt_icon":0},{"id":"2583355472","title":"康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2583355472","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583355472?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:32","pubTimestamp":1763022730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)(简称“吸入用结核病加强疫苗”)近日于印度尼西亚启动I期临床试验，并完成I期临床首例受试者入组。该I期临床试验于印度尼西亚开展，目的是在18-49岁的成年人中探究接种一剂吸入用肺结核疫苗(5型腺病毒载体)的安全性和免疫原性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","688185","BK0239"],"gpt_icon":0},{"id":"2582835429","title":"康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582835429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582835429?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:26","pubTimestamp":1762853198,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，康希诺报收于75.5元，较前一交易日下跌0.26%，最新总市值为186.82亿元。该股当日开盘75.81元，最高76.87元，最低74.71元，成交额达1.24亿元，换手率为1.43%。近日，康希诺生物股份公司发布2025年第二次临时股东大会会议资料，其中包含多项议案。公告显示，公司拟使用盈余公积和资本公积合计1,450,342,128.90元弥补母公司累计亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100028266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768434967789,"stockEarnings":[{"period":"1week","weight":0.0803},{"period":"1month","weight":0.1163},{"period":"3month","weight":-0.0272},{"period":"6month","weight":0.0587},{"period":"1year","weight":0.2466},{"period":"ytd","weight":0.1454}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17290人(较上一季度增加0.19%)","perCapita":"6614股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}